Amylin Pharmaceuticals and Takeda Pharmaceutical announced that they have suspended clinical activities in an ongoing Phase 2 study examining the safety and effectiveness of the investigational combination therapy pramlintide/metreleptin for the treatment of obesity. The clinical study was voluntarily halted to investigate a new antibody-related laboratory finding with metreleptin treatment …

The Southeastern US has been dubbed the “diabetes belt” with 644 mostly southern counties presenting above average rates of diabetes, according to new research by the CDC. There are more than 18 million diabetes sufferers nationwide, with a state pattern emerging for overall averages that matches known risk factors like …

Women who drink more than one cup of coffee a day could reduce their risk of stroke by 22% to 25%. A new study followed 34,670 Swedish women, ages 49 to 83, for an average of 10.4 years. Women who reported drinking little or no coffee had a higher risk …

Previous studies have suggested that soy intake may carry beneficial effects on glycemic control, but human intervention studies have yielded mixed results. A recent meta-analysis of 24 trials and more than 1,500 subjects found that soy consumption does not significantly affect measures of glycemic control. Researchers noted that there was …

How many carbs you eat might be less important for your blood sugar than your food’s glycemic load….

The finding may eventually lead to new ways to fight neuropathy, a condition that often accompanies other diseases including HIV/AIDS, diabetes and circulatory disorders….

A1c and cardiovascular risk scores identify those who can benefit from preventive interventions, according to the ADDITION study….

A physician’s empathy is an important factor associated with clinical competence….

Common variants are associated with glycemic response to metformin in Type 2 diabetes….

Tolerx, Inc., and GlaxoSmithKline (GSK) announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune Type 1 diabetes….